Genprex, Inc.
Clinical trials sponsored by Genprex, Inc., explained in plain language.
-
New Gene-Immuno combo aims to keep lung cancer at bay
Disease control Recruiting nowThis study tests a new gene therapy (quaratusugene ozeplasmid) combined with an immunotherapy drug (atezolizumab) as maintenance treatment for people with extensive-stage small cell lung cancer who have already responded to initial chemo-immunotherapy. The goal is to see if this …
Phase: PHASE1, PHASE2 • Sponsor: Genprex, Inc. • Aim: Disease control
Last updated May 26, 2026 08:40 UTC
-
Gene therapy combo shows promise for Drug-Resistant lung cancer
Disease control Recruiting nowThis study tests a new gene therapy (quaratusugene ozeplasmid) added to the standard drug osimertinib for people with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to osimertinib alone. About 158 adults with stage III or IV lung cancer will participa…
Phase: PHASE1, PHASE2 • Sponsor: Genprex, Inc. • Aim: Disease control
Last updated May 26, 2026 08:30 UTC